The Darwin Prospective Melioidosis Study: Years 27-31
Funder
National Health and Medical Research Council
Funding Amount
$1,281,718.00
Summary
The Darwin Prospective Melioidosis Study has documented 914 cases since 1989, with 115 fatalities. A surge in Darwin melioidosis cases over the past 5 years has been linked to urban development and the discovery of a new bacterial strain. Whole genome sequencing of our unique 25+ year set of bacteria and their linked patient data will unravel the changing epidemiology and identify important virulence factors, forming a foundation for future diagnostics, therapeutics, and vaccines.
Understanding The Role Of The Two Major Bacterial Pathogens In The Upper And Lower Airways Of Indigenous Children With Chronic Lung Disease
Funder
National Health and Medical Research Council
Funding Amount
$743,282.00
Summary
Lung infections are a major disease burden worldwide. Indigenous Australians are affected more; adults with severe lung disease can die in their 30s and 40s. These diseases start early, yet no in-depth studies of bacteria causing lung infections in children have been done. Our expert team proposes to use existing lung fluids from nearly 500 children with chronic lung disease (58% Indigenous), and state-of-the-art laboratory methods, to inform the design of vaccines to prevent lung disease.
Linking Genomics Of Burkholderia Pseudomallei To Melioidosis: Diversity Of Clinical Manifestations, Changing Epidemiology And Microevolution In Chronic Carriage.
Funder
National Health and Medical Research Council
Funding Amount
$602,769.00
Summary
The Darwin Prospective Melioidosis Study has documented 761 cases since 1989, with 102 fatalities. This study has led to improved therapy and public health initiatives. New technology to sequence whole bacterial genomes provides an opportunity to determine why urban melioidosis is increasing and to analyse this unique 22+ year set of bacteria and their linked patient data to find the important bacterial virulence factors, forming a foundation for future diagnostics, therapeutics, and vaccines.